U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H30O2
Molecular Weight 314.4625
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DRONABINOL

SMILES

CCCCCc1cc(c2[C@]3([H])C=C(C)CC[C@@]3([H])C(C)(C)Oc2c1)O

InChI

InChIKey=CYQFCXCEBYINGO-IAGOWNOFSA-N
InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including http://www.who.int/medicines/areas/quality_safety/4.2DronabinolCritReview.pdf

Dronabinol also known as (−)-trans-delta9-tetrahydrocannabinol is an active ingredient of cannabis. The drug was approved by FDA for the treatment of anorexia in patients with AIDS and chemotherapy-induced nausea and vomiting. Dronabinol exerts its action by activating CB1 and CB2 recepors which makes it a CNS active medicine.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P34972
Gene ID: 1269.0
Gene Symbol: CNR2
Target Organism: Homo sapiens (Human)
3.13 nM [Ki]
Target ID: P21554|||Q5UB37
Gene ID: 1268.0
Gene Symbol: CNR1
Target Organism: Homo sapiens (Human)
5.05 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MARINOL

Approved Use

MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Launch Date

4.86345605E11
Secondary
MARINOL

Approved Use

MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Launch Date

4.86345605E11
Secondary
MARINOL

Approved Use

MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Launch Date

4.86345605E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.88 ng/mL
10 mg 2 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
1.32 ng/mL
2.5 mg 2 times / day multiple, oral
dose: 2.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2.96 ng/mL
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
15.2 ng × h/mL
10 mg 2 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2.88 ng × h/mL
2.5 mg 2 times / day multiple, oral
dose: 2.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
6.16 ng × h/mL
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
10 mg 2 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
3%
2.5 mg 2 times / day multiple, oral
dose: 2.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
3%
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Other AEs: Palpitations, Tachycardia...
Other AEs:
Palpitations (2.5%)
Tachycardia (2.5%)
Photophobia (2.5%)
Vision blurred (2.5%)
Eye irritation (2.5%)
Dry mouth (40%)
Fatigue (30%)
Feeling of relaxation (5%)
Hunger (10%)
Feeling hot (5%)
Thirst (5%)
Chills (2.5%)
Upper respiratory tract infection (2.5%)
Hordeolum (2.5%)
Increased appetite (7.5%)
Polydipsia (2.5%)
Sensation of heaviness (2.5%)
Muscle spasms (2.5%)
Somnolence (37.5%)
Headache (10%)
Dizziness (5%)
Paraesthesia (2.5%)
Dysgeusia (5%)
Hypoaesthesia (2.5%)
Hypotonia (2.5%)
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
2.5 mg 2 times / day multiple, oral
Dose: 2.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 2 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Irritable Bowel Syndrome
Population Size: 10
Sources:
Other AEs: Headache...
Other AEs:
Headache (below serious, 3 patients)
Sources:
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 79
Health Status: unhealthy
Condition: Marijuana Addiction
Population Size: 79
Sources:
Other AEs: Diabetes, Concussion...
Other AEs:
Diabetes (serious, 1 patient)
Concussion (serious, 1 patient)
Nausea (below serious, 5 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache 10%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hunger 10%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Chills 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Eye irritation 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hordeolum 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hypoaesthesia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Hypotonia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Muscle spasms 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Palpitations 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Paraesthesia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Photophobia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Polydipsia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Sensation of heaviness 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Tachycardia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Upper respiratory tract infection 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Vision blurred 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Fatigue 30%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Somnolence 37.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Dry mouth 40%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Dizziness 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Dysgeusia 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Feeling hot 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Feeling of relaxation 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Thirst 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Increased appetite 7.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
unhealthy, mean age 36 years
n = 40
Health Status: unhealthy
Condition: cannabinoid abuse
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2016/205525Orig1s000MedR.pdf - p.40
Headache below serious, 3 patients
2.5 mg 2 times / day multiple, oral
Dose: 2.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 2 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Irritable Bowel Syndrome
Population Size: 10
Sources:
Nausea below serious, 5 patients
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 79
Health Status: unhealthy
Condition: Marijuana Addiction
Population Size: 79
Sources:
Concussion serious, 1 patient
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 79
Health Status: unhealthy
Condition: Marijuana Addiction
Population Size: 79
Sources:
Diabetes serious, 1 patient
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 79
Health Status: unhealthy
Condition: Marijuana Addiction
Population Size: 79
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes (pharmacogenomic study)
Comment: Published data indicate a 2- to 3-fold higher dronabinol exposure in individuals carrying genetic variants associated with diminished CYP2C9 function
Page: 13.0
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland.
1999 Aug
Acute injection of drugs with low addictive potential (delta(9)-tetrahydrocannabinol, 3,4-methylenedioxymethamphetamine, lysergic acid diamide) causes a much higher c-fos expression in limbic brain areas than highly addicting drugs (cocaine and morphine).
1999 Aug 25
Case report: adverse effects of taking tricyclic antidepressants and smoking marijuana.
1999 Nov
Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland.
2000 Apr 2
Cannabinoid CB(1) receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme.
2000 Feb 28
Cerebellar CB(1) receptor mediation of Delta(9)-THC-induced motor incoordination and its potentiation by ethanol and modulation by the cerebellar adenosinergic A(1) receptor in the mouse.
2000 May 12
An ab initio theoretical study of the stereoisomers of tetrahydrocannabinols.
2001 Apr
Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine.
2001 Apr
Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed.
2001 Apr 20
Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice.
2001 Aug 3
Cannabinoid receptors are absent in insects.
2001 Aug 6
Urine drug screens in overdose patients do not contribute to immediate clinical management.
2001 Feb
Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission.
2001 Jul
High rates of midazolam self-administration in squirrel monkeys.
2001 Jul
Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction.
2001 Jul
Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
2001 Jul 6
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.
2001 Jul 7
Interaction between delta-9-tetrahydrocannabinol and indomethacin.
2001 Jul-Aug
Concordance between verbal report and urine screen of recent marijuana use in adolescents.
2001 Jul-Aug
Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates.
2001 Jun
Delta(9)-THC stimulates food intake in Lewis rats: effects on chow, high-fat and sweet high-fat diets.
2001 Mar
Comparison of ELISAs for opiates, methamphetamine, cocaine metabolite, benzodiazepines, phencyclidine, and cannabinoids in whole blood and urine.
2001 Mar
Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones.
2001 Mar
Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation.
2001 Mar
Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation.
2001 May
The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.
2001 May
Critical role of the endogenous cannabinoid system in mouse pup suckling and growth.
2001 May 11
Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study.
2001 May 11
Interactions between A-9THC and capsaicin on isolated lamb bladder detrusor.
2001 May-Jul
[Antiarrhythmic properties of a cannabinoid (CB) receptor agonist].
2001 May-Jun
Cannabinoid-induced motor incoordination through the cerebellar CB(1) receptor in mice.
2001 May-Jun
A comparison of Roche Kinetic Interaction of Microparticles in Solution (KIMS) assay for cannabinoids and GC-MS analysis for 11-nor-9-carboxy-delta9-tetrahydrocannabinol.
2001 Oct
Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid.
2001 Oct
Electrophysiological evidence of serotonergic impairment in long-term MDMA ("ecstasy") users.
2001 Oct
Marijuana abstinence effects in marijuana smokers maintained in their home environment.
2001 Oct
The psychoactive ingredient of marijuana induces behavioural sensitization.
2001 Sep
Hu 210: a potent tool for investigations of the cannabinoid system.
2001 Summer
Patents

Sample Use Guides

Appetite Stimulation: Initially, 2.5 mg capsules should be administered orally twice daily, before lunch and supper. For patients unable to tolerate this 5 mg/day dosage, the dosage can be reduced to 2.5 mg/day, administered as a single dose in the evening or at bedtime. Antiemetic: it is best administered at an initial dose of 5 mg/m2, given 1 to 3 hours prior to the administration of chemotherapy, then every 2 to 4 hours after chemotherapy is given, for a total of 4 to 6 doses/day. Should the 5 mg/m2 dose prove to be ineffective, and in the absence of significant side effects, the dose may be escalated by 2.5 mg/m2 increments to a maximum of 15 mg/m2 per dose.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
DRONABINOL
HSDB   INN   MART.   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
INN   USAN  
Official Name English
.DELTA.1-THC
Common Name English
MARINOL
Brand Name English
QCD 84924
Code English
ABBOTT 40566
Code English
THC
Common Name English
SP 104
Code English
TETRAHYDROCANNABINOLS (-)-TRANS-.DELTA.9-FORM
MI  
Common Name English
TETRAHYDROCANNABINOL
Common Name English
(6AR,10AR)-6,6,9-TRIMETHYL-3-PENTYL-6A,7,8,10A-TETRAHYDRO-6H-DIBENZO(B,D)PYRAN-1-OL
Common Name English
DELTA-9-TETRAHYDROCANNABINOL
Common Name English
DELTA-9-THC
Common Name English
(6AR,10AR)-6A,7,8,10A-TETRAHYDRO-6,6,9-TRIMETHYL-3-PENTYL-6H-DIBENZO(B,D)PYRAN-1-OL
Common Name English
ABBOTT-40566
Code English
DRONABINOL [ORANGE BOOK]
Common Name English
J882F
Code English
.DELTA.9-THC
Common Name English
QCD-84924
Code English
DRONABINOL [VANDF]
Common Name English
DRONABINOL [INN]
Common Name English
TETRAHYDROCANNABINOL, DELTA-9 TRANS
Common Name English
SP-104
Code English
.DELTA.-9-TETRAHYDROCANNABINOL
Common Name English
6H-DIBENZO(B,D)PYRAN-1-OL, 6A,7,8,10A-TETRAHYDRO-6,6,9-TRIMETHYL-3-PENTYL-, (6AR,10AR)-
Common Name English
DELTA-9-TETRAHYDROCANNABINOL (CANNABIS SATIVA EXTRACT)
Common Name English
.DELTA.9-TETRAHYDROCANNABINOL
Common Name English
DRONABINOL [USAN]
Common Name English
(-)-.DELTA.1-3,4-TRANS-TETRAHYDROCANNABINOL
Common Name English
DRONABINOL [WHO-DD]
Common Name English
DRONABINOL [HSDB]
Common Name English
DRONABINOL [MART.]
Common Name English
DRONABINOL [USP MONOGRAPH]
Common Name English
NSC-134454
Code English
TETRAHYDROCANNABINOLS (-)-TRANS-.DELTA.9-FORM [MI]
Common Name English
6H-DIBENZO(B,D)PYRAN-1-OL, 6A,7,8,10A-TETRAHYDRO-6,6,9-TRIMETHYL-3-PENTYL-, (6AR-TRANS)-
Common Name English
Classification Tree Code System Code
NDF-RT N0000008010
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 668918
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
DEA NO. 7369
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
NCI_THESAURUS C267
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
LIVERTOX 947
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
WHO-ATC A04AD10
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 498215
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
CFR 21 CFR 1308.35
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 652218
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 54890
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
EU-Orphan Drug EU/3/16/1621
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
WHO-ATC N02BG10
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
NDF-RT N0000175782
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 628818
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
WHO-VATC QA04AD10
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 620417
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 549616
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 734820
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL465
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
RXCUI
10402
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
4109
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
IUPHAR
2424
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
INN
5547
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
EVMPD
SUB06407MIG
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
DRUG BANK
DB00470
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
EPA CompTox
1972-08-3
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
MERCK INDEX
M10624
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
TETRAHYDROCANNABINOL
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
LACTMED
Dronabinol
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
FDA UNII
7J8897W37S
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
MESH
D013759
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
NCI_THESAURUS
C867
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
PUBCHEM
16078
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
CAS
1972-08-3
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
HSDB
6471
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY